Wegovy, a medication based on semaglutide, has attracted significant attention in New Zealand due to its potential for substantial weight loss.The drug works by regulating appetite and blood sugar, helping people feel fuller for longer.Clinical trials indicate that, alongside lifestyle changes, participants can lose up to 15% of their body weight over around 68 weeks.

While this can reduce the risk of diabetes, heart disease, and other health issues, ongoing treatment is usually required, with weight often regained after stopping the drug.Side effects and long-term effects remain uncertain.

New Zealand has one of the highest obesity rates among developed nations, affecting both adults and children, with disproportionate impacts on Māori and Pacific communities due to socio-economic and environmental factors.

Factors such as the widespread availability of highly processed foods, aggressive marketing, and uneven school nutrition policies contribute to the problem.Local initiatives, like community 'food havens,' show how targeted interventions can improve access to healthy food.

Experts caution that while public funding for Wegovy may reduce long-term healthcare costs and improve equity, obesity is ultimately a systemic issue.

Addressing root causes—such as improving food environments, restricting unhealthy marketing, and tackling broader social inequalities—is necessary for lasting impact.Pharmaceutical solutions alone are unlikely to reverse New Zealand’s growing obesity epidemic.